SAVITZ RYAN (EVP, CFO & CBO) sold 31.25K shares of DIANTHUS THERAPEUTICS, INC. /DE/ on the open market
Open‑market sale worth $3.16M. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 7/13/2026ACC: 0001992324-26-000008
Officer· EVP, CFO & CBO
Since Feb 2026
-31.25K
Net shares
Net seller
$3.16M
Total sold
3
Open market trades
0B · 3S
5
Total transactions
31.25K acquired · 62.50K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+31.25K
Price / share
$21.77
Trade value
$680.29K
% of position
New position
7/9/2026
0.00→31.25K
Common Stock
Direct
Shares
−10.35K
Price / share
$100.22
Trade value
$1.04M
% of position
33.1%
7/9/2026
31.25K→20.89K
Common Stock
Direct
Shares
−15.33K
Price / share
$101.24
Trade value
$1.55M
% of position
73.4%
7/9/2026
20.89K→5.57K
Common Stock
Direct
Shares
−5.57K
Price / share
$101.97
Trade value
$567.57K
% of position
New position
7/9/2026
5.57K→0.00
Total
Net shares
+0.00
Net value
-$2.48M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/9/2026 | M · Option Exercise | +31.25K | $21.77 | $680.29K | New position | 0.00 | 31.25K |
| Common Stock Direct | 7/9/2026 | S · Sale | −10.35K | $100.22 | $1.04M | 33.1% | 31.25K | 20.89K |
| Common Stock Direct | 7/9/2026 | S · Sale | −15.33K | $101.24 | $1.55M | 73.4% | 20.89K | 5.57K |
| Common Stock Direct | 7/9/2026 | S · Sale | −5.57K | $101.97 | $567.57K | New position | 5.57K | 0.00 |
| Total | +0.00 | -$2.48M | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
31.25K shares
Shares
−31.25K
Strike price
21.77
Held after
68.75K
Exercisable
—
7/9/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock31.25K shares | 7/9/2026 | M · Option Exercise | −31.25K | 21.77 | — | 68.75K |